In a bid to strengthen its women’s health portfolio, Organon has agreed to acquire Forendo Pharma in a deal worth up to US$954 M. With the acquisition, Organon gains access to Forendo’s Phase II-ready asset, FOR-6219, which has the potential to be the first long-term therapy for patients with endometriosis. The announcement marks Organon’s third deal to date since its spinout from Merck in June 2021, following its acquisition of Alydia Health and partnership with ObsEva.